Skip to main content
SpringerLink
Log in

A case of anaphylaxis to alemtuzumab

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828

    Article  PubMed  CAS  Google Scholar 

  2. Coles AJ, CAMMS223 Trial Investigators Compston DAS, Selmaj KW, Lake SL, Moran S et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801

    Article  PubMed  Google Scholar 

  3. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839

    Article  PubMed  CAS  Google Scholar 

  4. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46(3):296–304

    Article  PubMed  CAS  Google Scholar 

  5. Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996 98(12):2819–2826

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Caon C, Namey M, Meyer C, Mayer L, Oyuela P, Margolin DH et al (2015) Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and rebif® efficacy in multiple sclerosis (CARE-MS) program. Int J MS Care 17(4):191–198

    Article  PubMed  PubMed Central  Google Scholar 

  7. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23(13):2971–2979

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The patient was treated on the NIHR Cambridge Clinical Research Facility.

Funding

The Medical Research Council funded the CAMTHY trial.

Author information

Authors and Affiliations

  1. University of Cambridge, Cambridge, UK

    Charles J. S. Nye

  2. Department of Allergy and Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    Annette Wagner

  3. Department of Clinical Neurosciences, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    Onajite Kousin-Ezewu, Joanne L. Jones & Alasdair J. Coles

Authors
  1. Charles J. S. Nye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Onajite Kousin-Ezewu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joanne L. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alasdair J. Coles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles J. S. Nye.

Ethics declarations

Conflicts of interest

Both AC and JJ have received honoraria and travel costs for attending scientific advisory boards.

Ethical standards

All human studies have been approved by the appropriate ethics committee and have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The patient in this case study gave her informed consent for the report to be written.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nye, C.J.S., Wagner, A., Kousin-Ezewu, O. et al. A case of anaphylaxis to alemtuzumab. J Neurol 266, 780–781 (2019). https://doi.org/10.1007/s00415-019-09214-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-019-09214-2

Search

Navigation